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is organised at national level, in close collaboration between ASN and 
radiotherapy professionals, leading to the publication of newsletters 
about the safety of patients. 
Taking into account one of the main findings of the international 
conference on Modern Radiotherapy, organised in 2009, by ASN, in 
Versailles (France), the European Commission decided to strengthen 
the European Basic Safety Standard introducing new requirements 
related to events reporting and risk analysis, and to launch the 
ACCIRAD project led by the Greater Poland Cancer Centre (GPCC, 
Poland)[1], following the goal to issue an European guidance on these 
topics in 2013. A general questionnaire sent to member states in 2012 
showed that more than half EU countries have already implemented in 
their legal system a requirement for risk analysis in radiotherapy, and 
classification, recording and reporting of adverse events and near 
misses. However, despite 15 years passed since 1997, in many EU 
countries the requirement for a legal framework regarding risk 
analysis and event’s classification, recording and reporting systems 
was not addressed and the practical implementation of the systems 
was still incomplete.A 2nd questionnaire, still being analysed, should 
allow to identify pertinent risk analysis methodologies used by 
radiotherapy centres and also good practices for event’s 
classification. On this basis, recommendations will be prepared by the 
ACCIRAD consortium to be included in the European guidance. The 
first results of these on going works will be presented at the  Geneva 
ESTRO conference in April 2013. 
   
 SYMPOSIUM: ADVANCED METHODS FOR TOXICITY 
PREDICTIVE MODELS  
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Characterising the dose-volume response of normal tissue structures is 
an important part of optimising radiotherapy treatment planning. 
However, understanding how the dose-distribution to a structure is 
related to outcome is confounded by co-morbidities and combinations 
of treatments as well as incomplete and inconsistent data.  One 
approach to this challenge is Machine Learning.  Machine learning 
describes models which learn from examples of a specific data type 
without a priori information about the relationship between the data.  
When both input variables and the corresponding outcome data are 
available, this known as supervised learning.  Once the relationship 
has been inferred it is possible to make prediction for previously 
unseen cases. 
The published literature on the use of machine learning approaches to 
model dose-volume effects utilise different algorithms.  Two 
commonly used supervised learning approaches are Artificial Neural 
Networks and Support Vector Machines. 
Artificial Neural Networks (ANN) are a (simplified) mathematical 
analogy of learning in the brain.  An ANN is trained by presenting 
example datasets to the network.  Input variables are propagated 
through a network of interconnected nodes and compared to the 
known outcome.  The weights of the connections between the nodes 
are altered iteratively so that the outcome is predicted correctly from 
the input data. 
Support vector machines (SVM) are used for dichotomised outcomes 
e.g. toxicity/no toxicity.  Separation between the two possible classes 
is achieved by translating the input variables in to a high-dimensional 
feature space where a boundary is derived to maximise the separation 
between the classes.    
An important consideration when developing a machine learning-based 
model is how to represent the input data.  This issue is not unique to 
machine learning and is also relevant to conventional statistical 
approaches.   When trying to predict radiation-induced toxicity the 
dose distribution to relevant structures need to be included. 
 Generally this is achieved by using summary measures such maximum 
dose and mean dose to the structure.  The dose-volume histogram can 
be reduced to a summary measure such as Equivalent Uniform Dose 
(EUD).  Often sequential variables describing the volume of the 
structure receiving a specified dose eg V5, V10, V15 etc are included.  
 A more detailed approach is to include a spatial description of the 
dose.  These dosimetric features will be combined with clinical 
information and information regarding other therapies such as 
chemotherapy. 
A successful model will be able to make predictions for previously 
unseen data.  Cross validation, where models are built on subsets of 
available data and tested and validated on independent samples, can 
ensure the ability of a model to generalise.  The effect of each 
variable on the ability of a model to make accurate predictions can be 
assessed with methods such as “leave one out” which as suggested 
repeats the process without a variable and assess the effect. 
This presentation will provide an overview of published literature on 
the modelling of dose-volume effects using machine learning.   A 
worked example of both ANN and SVM approaches to predict acute 
toxicity following head and neck radiotherapy will be used to 
demonstrate methodology.  The results will also be compared to a 
conventional multivariable analysis.   
Relatively little has been published on the use of machine learning 
approaches to the modelling of dose-volume effects.  However, they 
provide a complementary alternative to conventional statistical 
techniques. Consequently there is potential to further our 
understanding of the relationship between the dose distribution to a 
normal structure and corresponding radiation-induced toxicity. 
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It is well known that the risk of radio-induced toxicity increases when 
higher doses and larger volumes are involved in the irradiation and, in 
the last years, some consistent results have been published on the 
possible estimation of normal tissue complication probability (NTCP) 
for a number of organs-at-risk. The widespread method used for such 
calculations is based on a sigmoid dose-response curve coupled to 
reduction of the whole dose-volume histogram into one parameter 
(such as the equivalent uniform dose).  
NTCP models with their prediction based only on dosimetric variables 
can be used in treatment planning and can act as a baseline 
reference.  
On the other hand, it is becoming clearer that radiation-related side 
effects are also correlated to a number of patient-related factors. 
With the advent of newer radiotherapy technologies, which allow 
steep gradients and minimization of doses to normal tissues, there is 
an increased interest in understanding clinical/genetic risk factors 
that might enhance patient radio-sensitivity and to develop NTCP 
models which might include these variables in order to achieve better 
normal tissue complication predictions.  
Some recently published studies have shown that current NTCP models 
can be improved by incorporating clinical risk factors into model 
formulation. Overview of published results will be presented. 
A further important step is the inclusion of molecular/genetic 
predictors into NTCP models. This issue is still at a very primitive 
stage  and should be elucidated because, given the same set of 
clinical/dosimetric factors, patient-to patient variability in normal 
tissue response to radiation has been widely recognized in clinical 
practice, suggesting that this phenomenon might be, at least in part, 
genetically driven. 
In this presentation data on molecular/genetic markers influencing 
radio-induced toxicity are presented, together with the first findings 
supporting the hypothesis that a genetically determined dose–response 
relationship is possible and could be used to predict the probability of 
side effects associated with radiotherapy and serve as a rational basis 
for individualized radiation dose prescriptions. 
The future lies in these multi-factorial prediction models: a great 
effort has to be done to collect reliable detailed prospective data for 
the development of NTCP models with the inclusion of predisposing 
clinical/geneticfeatures for normal tissues involved in radiotherapy. 
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Trismus, which results in difficulty, restriction or pain when opening 
the mouth (CTCAE), is a common complication in head and neck 
cancer patients following radiotherapy and leads to degradation in 
quality of life. There are few studies that have addressed radiation 
induced trismus. However, the main cause remains poorly understood. 
Studies have attributed trismus to the irradiation of a range of organs 
at risk (OAR) such as the mastication muscles, the temporomandibular 
joint (TMJ), and pterygoid plate among others.  
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Current normal tissue complication probability (NTCP) models rely 
heavily on dosimetric parameters that are derived from dose-volume 
histograms (DVHs) which lack the spatial information. These 
parameters assume a homogenous response to radiation and tend to 
ignore any inter or intra-organ variation in radiosensitivity. To address 
these issues in our analysis, we developed an image-based approach 
which utilizes the full 3D dose distribution and does not assume any 
prior knowledge of the OARs. Using image registration, we deformed 
CT scans, anatomic structures, and 3D dose distributions from a 
patient cohort onto the same frame of reference “standard patient”. 
Voxel-based correlations between dose and the complication endpoint 
(trismus) were computed over the entire voxel space to construct a 3D 
correlation map. 
We applied this methodology to a cohort of 110 oropharyngeal cancer 
(OPC) patients treated with IMRT and Chemotherapy at MSKCC 
between 2004 and 2009. The results showed a good agreement 
between the image-based approach and the standard NTCP models. 
Both approaches showed a statistically significant correlation between 
the dose to mastication muscles and trismus. Furthermore, the voxel-
wise 3D correlation map provided additional information and revealed 
regions of high correlation outside the mastication muscle region 
which might suggest the involvement of other organs or tissues at risk. 
However, the clinical implication of these new findings needs further 
investigation in an independent data set and might be related to beam 
arrangement and configuration. 
In addition, we also developed a new metric to estimate the 
geometric uncertainty of the underlying deformable registration which 
we denote as distance discordance (DD). More technical details and a 
few examples will be presented to illustrate the concept of DD and its 
impact on the uncertainty of dose mapping. In summary, this study 
demonstrates the validity of this approach and emphasizes the need 
to consider the full 3D dose distribution in conjunction with DVH 
analysis.  
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Many new treatment units are already on the market that operate 
without a flattening filter (FF) or can be operated in a dedicated 
clinical flattening filter free (FFF) mode, i.e. Tomotherapy, 
Cyberknife, Varian’s True-Beam or ELEKTA’s Agility linacs, 
respectively. The commonly accepted dosimetric benefits of FFF high 
energy photon beams, which range from increased dose rate and dose 
per pulse, to favorable output ratio in-air variation with field size, 
reduced energy variation across the beam, reduced leakage and out-
of-field dose, respectively, imply new dosimetric challenges. These 
are related to beam quality specification, beam calibration, small 
field dosimetry, acceptance testing/commissioning, regular quality 
assurance procedures, and finally treatment plan verification.  
As far as the acquisition of basic relative beam parameters is 
concerned, the commissioning of a FFF treatment delivery unit is not 
very different from a standard linac. However, the increased dose 
rate and the high dose per pulse needs to be considered,since some 
point detectors show a pronounced dose rate dependency (e.g. 
diamond detector, liquid filled ionization chamber), possible 
saturation or reduced collection efficiency.  
The forward peaked dose distribution of FFF beams is fundamentally 
different and makes standard parameters as used for quality control 
of linacs, e.g. homogeneity, field flatness and beam penumbra, not 
always viable. Recently suggestions have been made to overcome this 
issue in clinical dosimetry.  
Small field dosimetry is of special importance since all relevant 
clinical applications of FFF beams are closely related to high precision 
radiotherapy techniques, i.e. stereotactic RT or IMRT, where small 
fields/segments build the basis for treatment delivery. 
Today’s challenge of small beam dosimetry and its link to absorbed 
dose determination in reference geometry is enhanced by unflattened 
beams and dedicated high precision radiotherapy delivery units that 
do not allow to setup the reference conditions, as defined by the IAEA 
TRS 398 or AAPM TG 51 codes of practice. Incorrectly measured beam 
output in small beams can result in systematic uncertainties when 
implementing basic beam data in treatment planning systems(TPS), 
misleading results in acceptance testing/ commissioning of a TPS, and 
finally erroneous patient treatments leading to radiation incidents or 
accidents. Therefore correction factors for a variety of commercially 
available small ion chambers and other radiation detectors are 
currently being investigated in order to extend their use towards small 
beam dosimetry in FFF photon beams. 
The accuracy of dose calculation in TPS represents another dosimetric 
aspect. Several studies demonstrated that inverse planning tools for 
IMRT are able to handle unflattened beams and that the dose 
calculation accuracy of commercial TPS is not impaired when 
removing the FF. 
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The advent of the Flattening Filter Free beams (FFF) available on 
common linacs, is facing the community to the ability of treatment 
planning system to accurately model such beams, and with the 
understanding of which are the best sites and treatments which could 
take advantages from using FFF beams. An overview of the published 
data on dose calculation algorithms accuracy for FFF fields is given. 
The characteristics of the FFF beams are here analyzed to evaluate 
the clinical sites where such beams could take advantage. The main 
characteristics relate to the out-of-field dose (peripheral dose) that 
could lower the organs at risk dose; to the high dose rate, allowing 
shorter treatment time for stereotactical treatments; to the profile 
shape that could be better suitable for small targets or simultaneous 
integrated boost treatments.  
A review of published planning studies presents plan comparisons in 
different sites. Prostate, lung, brain, head and neck plans were 
evaluated for IMRT treatment with different beams (6 and 18 MV, 
flattened and unflattened). Also whole breast plans (with different  
techniques from tangents to IMRT) and esophageal treatment 
(conformal, IMRT, VMAT) where analysed by different groups. Results 
of such studies presenting rather large volumes showed no significant 
difference in plan quality between standard flattened and FFF beams. 
A substantial reduction of MUs and consequently of radiation outside 
the target was evidentiated for most of sites, although the opposite 
could be found for very large (or very elongated) targets, where the 
lower off-axis dose would play an unbeneficial role.  
The lower radiation dose outside the target was also studied on 
anthropomorphic phantom to simulate pediatric IMRT treatments with 
FFF beams in the intracranial regions. The measured dose reduction in 
the periphery (from thyroid to ovaries and testes) was lower of 23 to 
70% relative to the standard flattened beams. 
Particular attention is paid to stereotactical treatments, where the 
high dose rate is the clear and natural benefit in treating with FFF 
beams. Studied sites were early stage lung treatments, liver 
metastases and pelvic/abdominal metastases. 
Examples of lung and brain stereotactical comparisons with and 
without flattening filter are given. 
Conclusions: there are benefits in using FFF beams for some 
treatment site and lesion sizes. The primary benefit is, for high dose 
per fraction treatments, the high dose rate that reduces the beam-on 
time. Other proven benefits are the lower out-of-field and peripheral 
dose, that decrease the critical structures dose and the risk of 
secondary cancer induction. 
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Flattening filter free (FFF) options are now commercially available 
and treatments utilising the higher dose-rates obtained are being 
introduced into clinical use. Removal of the flattening filter results in 
an increase, by a factor of 2-6 times, in the instantaneous dose-rate 
of the x-ray pulse compared to the standard flattened beams. The 
increased dose per pulse, result in an equivalent increase in the 
average dose-rate and a potentially similar reduction in overall 
treatment time. The potential radiobiological factors that result from 
changing the instantaneous dose-rate include potential changes to 
sub-lethal damage repair mechanisms, potential synergistic effects 
and the potential radiobiological effects resulting from changes to the 
overall treatment time. A number of in-vitro studies have been 
undertaken using x-ray beams from linear accelerators designed 
specifically to study the implications of changes in dose-rate of the 
treatment beams resulting from treating with flattening filter free 
beams. These studies have used a variety of experimental 
methodologies to achieve the required instantaneous dose-rates and 
differing ways to ensure dose uniformity over the in-vitro flask. These 
differences in the experimental methodologies have not led to 
